Evidence map›Paper›PMID 39847481›Full record

ArticleCell reports2025

CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells.

Kiel T Tietz, Braedan M McCluskey, Conor R Miller, Yingming Li, Sarah A Munro, Scott M Dehm

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kiel T TietzMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Braedan M McCluskeyMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN 55455, USA.
Conor R MillerMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Yingming LiMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Sarah A MunroMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN 55455, USA.
Scott M DehmMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: dehm@umn.edu.

Funding

AR Gene Rearrangements and AR Signaling in Prostate CancerR01CA174777 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2013 to 2026
$4.9M
Targeting early events in prostate cancer lineage plasticityR01CA270539 · NCI · UNIVERSITY OF MINNESOTA · PI Scott M. Dehm · 2023 to 2026
$1.8M
NCI NIH HHS R01 CA174777NCI NIH HHS R01 CA270539NCI NIH HHS T32 CA00913
6 · The paper itself

Abstract

Localized prostate cancer can be cured by radiation or surgery, but advanced prostate cancer continues to be a clinical challenge. Altered alternative polyadenylation occurs in numerous cancers and can downregulate tumor-suppressor genes and upregulate oncogenes. We found that the cleavage and polyadenylation specificity factor (CPSF) complex factor CPSF1 is upregulated in patients with advanced prostate cancer, with high CPSF1 expression correlating with worse progression-free survival. Knockdown of CPSF1 selectively inhibited the growth of prostate cancer cells and reduced glycolytic output. Evaluating the changes in global poly(A) site usage in prostate cancer cells following CPSF1 knockdown revealed widespread usage of intergenic poly(A) sites distal to annotated 3' UTRs, which lengthened 3' UTRs and decreased levels of thousands of mRNAs, including key glycolysis genes. These findings uncover a role for CPSF1 in the suppression of intergenic poly(A) sites in prostate cancer and nominate CPSF1 as a therapeutic target in advanced prostate cancer.

Indexed as

Cleavage And Polyadenylation Specificity FactorGlycolysisPolyadenylationProstatic Neoplasms3' Untranslated RegionsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMaleRNA, Messenger3' Untranslated RegionsCleavage And Polyadenylation Specificity FactorRNA, MessengerCP: CancerCP: Molecular biologyCPSF1glycolysisintergenic polyadenylationprostate cancer

Identifiers

PMID39847481
PMCPMC11831233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.